Chronic myeloid leukemia (CML), caused by constitutively active BCR-ABL1 fusion tyrosine
kinase, has served as a paradigm for successful application of molecularly targeted cancer …

Chronic myeloid leukemia (CML) is caused by BCRABL1 in a cell with the biological
potential, intrinsic or acquired, to cause leukemia. This cell is commonly termed the CML …

Activation of Janus kinase 2 (JAK2) by chromosomal translocations or point mutations is a
frequent event in haematological malignancies,,,,,. JAK2 is a non-receptor tyrosine kinase …

Pediatric acute lymphoblastic leukemia (ALL) is a heterogeneous disease consisting of
distinct clinical and biological subtypes that are characterized by specific chromosomal …

Despite some exciting new leads in molecular pathogenesis, AIDS-defining primary effusion
lymphoma (PEL) remains a fatal malignancy. The lack of substantial progress in the …

Hematopoiesis is the cumulative result of intricately regulated signaling pathways that are
mediated by cytokines and their receptors. Studies conducted over the past 10 to 15 years …

The twenty-first century is beginning with a sharp turn in the field of cancer therapy.
Molecular targeted therapies against specific oncogenic events are now possible. The BCR …

The B cell lineage of the hematopoietic system is responsible for the generation of high-
affinity antibodies, which provide humoral immunity for protection against foreign pathogens …

Constitutive activation of STAT5 is critical for the maintenance of chronic myeloid leukemia
(CML) characterized by the BCR-ABL oncoprotein. Tyrosine kinase inhibitors (TKIs) for the …

Abstract In BCR-ABL1+ leukemia, drug resistance is often associated with up-regulation of
BCR-ABL1 or multidrug transporters as well as BCR-ABL1 mutations. Here we show that the …